GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Absci Corp (NAS:ABSI) » Definitions » Equity-to-Asset

Absci (ABSI) Equity-to-Asset : 0.87 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Absci Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Absci's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $240.11 Mil. Absci's Total Assets for the quarter that ended in Mar. 2024 was $274.90 Mil. Therefore, Absci's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.87.

The historical rank and industry rank for Absci's Equity-to-Asset or its related term are showing as below:

ABSI' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.11   Med: 0.86   Max: 0.87
Current: 0.87

During the past 5 years, the highest Equity to Asset Ratio of Absci was 0.87. The lowest was -2.11. And the median was 0.86.

ABSI's Equity-to-Asset is ranked better than
79.47% of 1559 companies
in the Biotechnology industry
Industry Median: 0.67 vs ABSI: 0.87

Absci Equity-to-Asset Historical Data

The historical data trend for Absci's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Absci Equity-to-Asset Chart

Absci Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
-2.11 -1.01 0.86 0.86 0.81

Absci Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 0.85 0.83 0.81 0.87

Competitive Comparison of Absci's Equity-to-Asset

For the Biotechnology subindustry, Absci's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Absci's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Absci's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Absci's Equity-to-Asset falls into.



Absci Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Absci's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=176.176/217.298
=0.81

Absci's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=240.107/274.898
=0.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Absci  (NAS:ABSI) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Absci Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Absci's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Absci (ABSI) Business Description

Traded in Other Exchanges
N/A
Address
18105 SE Mill Plain Boulevard, Vancouver, WA, USA, 98683
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Executives
Frans Van Houten director 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Daniel A Rabinovitsj director 400 W CESAR CHAVEZ, AUSTIN TX 78701
Andreas Busch director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Sarah Korman officer: General Counsel 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98660
Todd Bedrick officer: VP, CCPAO 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Joseph Sirosh director C/O COMPASS, INC., 155 AVENUE OF THE AMERICAS, SIXTH FLOOR, NEW YORK NY 10013
Sean Mcclain director, 10 percent owner, officer: President and Chief Executive 18105 SE MILL PLAIN BLVD, SUITE 350, VANCOUVER WA 98683
Zachariah Jonasson director 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Eli Casdin director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Partners Master Fund, L.p. director, 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Karen K Mcginnis director INSIGHT ENTERPRISES INC, 1305 WEST AUTO DRIVE, TEMPE AZ 85284
Redmile Biopharma Investments Ii, L.p. director, 10 percent owner LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129
Phoenix General Partner Ii Llc 10 percent owner 1700 S. EL CAMINO REAL, SUITE 335, SAN MATEO CA 94402
Nikhil Goel officer: Chief Business Officer 101 E. 6TH STREET, SUITE 350, VANCOUVER WA 98660